新型双相脉冲场消融导管与热消融治疗阵发性房颤的InsightPFA试验
InsightPFA为前瞻性多中心随机对照试验,纳入中国13中心287例症状性阵发性房颤患者,1:1比较纳秒脉冲场消融(nsPFA)与消融指数指导射频消融(RFA)行肺静脉隔离。主要疗效终点全分析集中nsPFA组65.5%与RFA组64.1%达标(校正率差2.0%,95%CI -8.7%~12.8%,非劣效P=0.0019),12个月Kaplan-Meier成功率66.7% vs 67.4%(HR 0.99,95%CI 0.66~1.48,非劣效P=0.0020),两组操作相关不良事件无显著差异,nsPFA组总手术时间、左房停留时间和消融时间更短,但透视时间更长、辐射剂量更高,且无需全身麻醉。
要点
- nsPFA在12个月无房性快速性心律失常复发且未用I/III类抗心律失常药方面非劣于AI指导RFA。
- 两组操作相关不良事件发生率无显著差异,急性手术成功率均为100%。
- nsPFA缩短总手术时间、左房停留时间和消融时间,但透视时间更长、辐射剂量更高。
核心结论
- 纳秒脉冲场消融(nsPFA)在症状性阵发性房颤肺静脉隔离中疗效非劣于消融指数指导射频消融,安全性相当,且无需全身麻醉。
- nsPFA显著缩短总手术时间和左房停留时间。
研究设计与样本
- InsightPFA为前瞻性、多中心、随机对照试验,在中国13个中心纳入287例患者,1:1随机分配至nsPFA组或消融指数指导RFA组行肺静脉隔离,完成标准化12个月随访。
- 141例nsPFA患者和142例AI指导RFA患者完成随访。
主要发现
- 主要疗效终点在全分析集中nsPFA组93例(65.5%)与RFA组93例(64.1%)达标,校正率差2.0%(95%CI -8.7%~12.8%),非劣效P=0.0019。
- 12个月Kaplan-Meier治疗成功率nsPFA组66.7%、RFA组67.4%(HR 0.99,95%CI 0.66~1.48),非劣效P=0.0020。
- 两组操作相关不良事件发生率无显著差异,急性手术成功率均为100%。
- nsPFA组总手术时间、左房停留时间和消融时间显著更短,但透视时间更长、辐射暴露剂量更高。
- 清醒镇静使用比例nsPFA组89.4%、RFA组92.4%。
临床怎么用
- 对于症状性阵发性房颤患者,nsPFA可作为AI指导RFA的非劣效替代方案,且无需全身麻醉。
- nsPFA可缩短总手术时间和左房停留时间,但需注意透视时间延长和辐射剂量增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical performance of a novel nanosecond pulsed field ablation (nsPFA) system (Insight Medtech) for pulmonary vein isolation in patients with paroxysmal atrial fibrillation remains unclear. OBJECTIVES: This trial sought to evaluate the efficacy and safety of nsPFA vs ablation index (AI)-guided radiofrequency ablation (RFA) for symptomatic atrial fibrillation. METHODS: The InsightPFA trial was a prospective, multicenter, randomized controlled trial. Patients were randomly allocated in a 1:1 ratio to receive either nsPFA or ablation index (AI)-guided RFA for pulmonary vein isolation. Participants completed a standardized 12-month follow-up protocol. The primary efficacy endpoint was defined as freedom from documented atrial tachyarrhythmia recurrence without the use of class I or III antiarrhythmic drugs. The safety assessment evaluated death, stroke, transient ischemic attack, procedure- and device-related events, and other adverse outcomes in both groups. Secondary efficacy endpoints included acute procedural success and procedural evaluations. RESULTS: Among 287 patients from 13 centers in China, 141 nsPFA patients and 142 AI-guided RFA patients completed follow-up. The proportions of conscious sedation use were 89.4% in the nsPFA group and 92.4% in the AI-guided RFA group. The primary efficacy endpoint was achieved in 93 (65.5%) patients in the nsPFA group and 93 (64.1%) in the AI-guided RFA group in the full analysis set population (adjusted rate difference: 2.0%; 95% CI: -8.7% to 12.8%; P = 0.0019 for noninferiority), demonstrating that the noninferiority was met. The 12-month Kaplan-Meier treatment success rates were 66.7% and 67.4% in the nsPFA and AI-guided RFA groups, respectively (HR in the PFA group: 0.99; 95% CI: 0.66 to 1.48; P = 0.0020 for noninferiority). There was no significant difference in the incidence of procedure-related adverse events between the 2 groups. Acute procedural success rates were 100% in both groups. The nsPFA group demonstrated significantly shorter total procedure time, left atrial dwell time, and ablation time but experienced longer fluoroscopy times and higher radiation exposure doses. CONCLUSIONS: The nsPFA exhibited noninferior efficacy and comparable safety to AI-guided RFA while obviating the need for general anesthesia. Furthermore, the study revealed that this ablation technique significantly reduced both total procedure time and left atrial dwelling time. (InsightPFA Trial of the LotosPFA Catheter [InsightPFA]; NCT06014996).
引用
- Lin, Chu, Wang, et al. Pulsed Field Ablation Using a Novel Biphasic Catheter vs Thermal Ablation for Paroxysmal Atrial Fibrillation: InsightPFA Trial. J Am Coll Cardiol. 2025. PMID: 41338842. doi:10.1016/j.jacc.2025.09.1593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。